Hints and tips:
Related Special Reports
Related Topics
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Pfizer said: “We are confident in our IP position around Comirnaty and intend to vigorously defend against these claims.”...
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...BioNTech and Pfizer have said the patents are invalid....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...Read more on Pfizer here...
...Andrea Chiarello, Pfizer’s head of EU government affairs, said drugmakers needed more encouragement to discover new antimicrobials and develop drugs....
...Data on Pfizer’s once-daily oral pill is expected in the first half of 2024. Its shares fell 4.3 per cent lower before the open in New York. Read more on Pfizer here...
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...Pfizer swung to a loss in the third quarter after a $5.6bn inventory write-off related to its Covid-19 antiviral and vaccine....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Pfizer revised its full-year revenue guidance to a range between $58bn and $61bn, down from $67bn-$70bn, “solely due to Covid products”, it said....
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...Moderna alleges that Pfizer and BioNTech infringed on two of its patents in their use of the critical mRNA platform. BioNTech and Pfizer say the patents are invalid....
...Haleon was born as a joint venture between Pfizer and GSK in 2019 that sat within GSK, before it was spun off via a UK listing in 2022, leaving GSK and Pfizer with 13.5 per cent and 32 per cent of the business...
...Pfizer’s revenue more than halved in the second quarter, after demand for its Covid-19 products fell sharply....
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...The maker of Panadol painkillers, which was spun off from GSK and Pfizer in 2022, said it expected organic revenue growth of 4-6 per cent in 2024, ahead of analyst estimates of 4.5 per cent....
International Edition